Management
Kristina Torfgård
Chief Executive Officer since 2019
Kristina has 30 years of experience in drug development from leading roles in the pharmaceutical and biopharma industry. She has previously worked at AstraZeneca with research and development in both early and late phase and has been globally responsible for marketed products. Kristina has also worked at the biopharma company Albireo AB/Pharma Inc, as VP Clinical & Regulatory Affairs and VP Global Project Head and was engaged in building the company.
Shareholdings and warrants:
50 000 shares
Warrants granting acquisition rights to:
53 000 shares (2020/2023, incentive program)
Education: MSc Pharmacy, PhD in Clinical Pharmacology
Other assignments: Board member of GU Ventures
Anders Sandberg
Chief Scientific Officer since 2015
Anders is one of Alzinova’s co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on neurotoxic peptide devices. Anders has since 2007 worked with the ALZ-101 and ALZ-201 projects as its main occupation, and as chief operating officer has run much of the Company’s operations since it was founded in 2011. He is also a co-inventor of Alzinova’s AβCC technology and has been a deputy board member since 2011.
Shareholdings and warrants:
167 693 shares
Warrants granting acquisition rights to:
10 500 shares (2020/2023, incentive program)
Education: PhD in Chemistry
Other assignments: –
Håkan Skogström
Chief Financial Officer since 2020
Håkan has more than 25 years of experience from leading finance positions in the shipping industry. He has previously worked as CFO and CEO at a privately owned Swedish shipping company with international operations where he has been involved in building the company. Håkan worked as CFO for Safe at Sea AB. Håkan also works as financial consultant for small and medium-sized companies.
Shareholdings and warrants:
34 000 shares
Warrants granting acquisition rights to:
21 000 shares (2020/2023, incentive program)
Education: BSc Business and Economics, Small business management
Other assignments: –
Sebastian Hansson
Business Development Director since 2023
Sebastian has 15 years of experience from pharmaceutical R&D and clinical development, CRO:s and GMP production of APIs (Active Pharmaceutical Ingredients). He has extensive experience in startups and business development. Before joining Alzinova he has been Chief Operating Officer at SWIPP AB, project manager and Key Account Manager at Polypeptide Group and Business development manager at Solve R&C.
Shareholdings and warrants:
Shares: 24 000
Education: MSc in Chemistry, PhD in Molecular Biophysics, MBA, Certified Board Member.
Other assignments: Board member of Bulb Intelligence AB, Tyto Competitive Intelligence Solutions AB and Scientific Intelligence Consulting Öresund AB.
Stefan Pierrou
Development Project Director since 2021
Stefan has 25 years experience of drug discovery and development. He has worked as a pre-clinical research manager and early clinical project leader to bring compounds for clinical testing and beyond. Stefan worked at AstraZeneca in different project leading and managerial roles in research and development. He also works as a senior consultant supporting smaller biotech and drug development companies
Shareholdings and warrants:
7 925 shares
Education: MSc Chemical Engineering, PhD Molecular Biology
Other assignments: CEO, ESP Life Science Consulting AB
Sandra Bevan
Clinical Development Director since 2022
Sandra has more than 25 years of experience of strategic and operational global drug development from pharmaceutical and biotech companies. She worked at AstraZeneca in global clinical development and cross-functional project management positions predominately in the neuroscience area. She also works as a senior pharmaceutical clinical development consultant supporting small and medium sized biotech and drug development companies in different operational and leadership roles in all phases of clinical development. Prior to joining the industry, she worked as a Registered Nurse in the UK’s NHS.
Shareholdings and warrants: –
Education: MSc in Health Sciences
Other assignments: Owner and Senior Pharmaceutical Clinical Development Consultant for Bevan Consulting AB.